Advertisement
top banner image  

topleft corner image     top right corner image
 
ACCF/AHA Clinical Guidelines and Statements

CME logo image
bullet
bullet
bullet
bullet

JACC Homepage JACC Imaging Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?

take action
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

acc links
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

jacc interventions image
bullet
bullet
bullet
bullet

     top nav image

     

J Am Coll Cardiol Intv, 2008; 1:111-121, doi:10.1016/j.jcin.2008.01.005
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kereiakes, D. J.
Right arrow Articles by Gurbel, P. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kereiakes, D. J.
Right arrow Articles by Gurbel, P. A.

State-of-the-Art Paper

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

Dean J. Kereiakes, MD, FACC*,*, Paul A. Gurbel, MD, FACC{dagger}

* Christ Hospital Heart and Vascular Center/the Lindner Research Center, Cincinnati, Ohio
{dagger} Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland.

* Reprint requests and correspondence: Dr. Dean J. Kereiakes, The Lindner Research Center, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219. (Email: lindner{at}fuse.net).

Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-µmol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.

Abbreviations and Acronyms
  ADP = adenosine diphosphate
  COX = cyclooxgenase
  GP = glycoprotein
  MACE = major adverse cardiac events
  PAR = protease-activated receptor
  PCI = percutaneous coronary intervention
  UFH = unfractionated heparin




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
G. W. Reed and C. P. Cannon
Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein.
J. Am. Coll. Cardiol., December 13, 2011; 58(25): 2640 - 2641.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Kornowski, R. Mehran, G. Dangas, E. Nikolsky, A. Assali, B. E. Claessen, B. J. Gersh, S. C. Wong, B. Witzenbichler, G. Guagliumi, et al.
Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction: Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol., August 9, 2011; 58(7): 704 - 711.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
V. A. Ferraris, J. R. Brown, G. J. Despotis, J. W. Hammon, T. B. Reece, S. P. Saha, H. K. Song, E. R. Clough, L. J. Shore-Lesserson, L. T. Goodnough, et al.
2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
Ann. Thorac. Surg., March 1, 2011; 91(3): 944 - 982.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Gurbel, U. S. Tantry, A. R. Shuldiner, and D. J. Kereiakes
Genotyping: One Piece of the Puzzle to Personalize Antiplatelet Therapy
J. Am. Coll. Cardiol., July 6, 2010; 56(2): 112 - 116.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
Y.-H. Jeong, I.-S. Kim, Y. Park, M.-K. Kang, J.-S. Koh, S.-J. Hwang, C. H. Kwak, and J.-Y. Hwang
Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study
J. Am. Coll. Cardiol. Intv., July 1, 2010; 3(7): 731 - 741.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
P. A. Gurbel, U. S. Tantry, and A. R. Shuldiner
The Worry About Clopidogrel "Nonresponsiveness": Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient
J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1102 - 1104.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1438 - 1446.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. O. Williams and J. D. Abbott
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Circulation, September 16, 2008; 118(12): 1219 - 1222.
[Full Text] [PDF]



Advertisement
 
   
 
home link current link search link archive link topics link cardiology careers link